QT Imaging (QTI) Q2 2026 earnings review
Revenue Doubles, but Margin Compression and Cash Burn Persist
QT Imaging continues to execute on its hardware distribution backlog, delivering 103% YoY revenue growth in Q2 with $7.4M on 15 scanner shipments. However, the volume growth masks underlying structural challenges. Gross margin compressed to 41% from 50% a year ago, which management admits is the expected run-rate for U.S. sales. Operating expenses surged 71% YoY, and a massive $8.3M non-cash debt modification charge pushed net loss to $11.1M. While a recent $10M public offering and a two-year loan extension provide temporary breathing room, the company's aggressive $39M full-year revenue target requires a massive, unproven back-half ramp.
🐂 Bull Case
Secured key regulatory authorizations in Saudi Arabia (FDA) and Israel (AMAR), which immediately clear the path to execute on minimum order quantities with international distributors like Gulf Medical.
The company is evolving beyond hardware, advancing its QTI Precision Pathway cloud platform and multi-modality viewers. This lays the groundwork for high-margin, recurring software revenue.
🐻 Bear Case
Gross margins are stabilizing at an unimpressive ~41%. If U.S. distributor pricing dictates this margin profile, the hardware business will struggle to generate enough cash to offset rising R&D and SG&A.
With only $14.0M recognized in H1, the company must deliver $25.0M in H2 to meet its $39M guidance. This implies a massive acceleration heavily dependent on lumpy distributor shipments.
⚖️ Verdict: 🔴
Bearish. Top-line growth is mechanically driven by contractual minimums, but the unit economics are deteriorating. High cash burn, mounting debt costs, and low gross margins outshine the revenue wins.
Key Themes
The True Cost of Distributor Growth
Gross margin dropped significantly to 41% from 50% in 25Q2. More concerningly, management noted this margin is 'in line with our projections for sales in the USA.' This contradicts the narrative of scaling economics; as QT Imaging relies on partners like NXC/Canon for volume, they are sacrificing pricing power and locking in a lower structural margin profile.
Direct Sales Strategy Launched to Defend Margins
To counter the margin squeeze from distributors, QT Imaging is pivoting to a hybrid commercial model. The appointments of seasoned sales VP's (Jason Dyer and Dave Reinhart) to target enterprise health systems directly is a critical driver for future margin expansion and deeper clinical penetration in the U.S.
Global Regulatory Dominoes Falling
International expansion is a primary growth engine. Gaining AMAR authorization in Israel and FDA clearance in Saudi Arabia are massive catalysts. These approvals transition Middle Eastern distributor contracts from speculative backlogs into active, recognizable revenue streams.
Tailwinds from FDA Breast Density Rules
The macro environment is shifting in QT's favor. With new FDA guidelines advising patients to consider breast density alongside cancer risk, the total addressable market for supplemental, radiation-free imaging is expanding. This perfectly positions the Breast Acoustic CT against traditional mammography.
Technology Innovation Validated
The company continues to fortify its competitive moat. A recent multi-site study proved the system's Speed of Sound measurement variability is less than 1%. Combined with a flawless routine FDA inspection (zero Form 483 observations) and software updates (version 4.5.0) that improve resolution by 40-50%, the clinical utility of the Breast Acoustic CT is accelerating.
Cost Cutting Claims Contradicted by Surging OpEx
Management touted moving to a new 22,000-square-foot facility in Petaluma, claiming it reduces lease costs per square foot by 55%. However, total operating expenses actually surged 71% YoY (from $2.87M to $4.92M) driven by headcount, professional fees, and marketing. Operational leverage remains elusive.
Other KPIs
Cash burn accelerated sharply in Q2, jumping from a $1.4M burn in the prior year to $4.8M. Despite raising $10M via a public offering, ending cash of $11.0M (up to $14.2M by early August) provides roughly three quarters of runway if this burn rate persists.
A massive drag on net income. The company extended its Lynrock Lake term loan maturity from 2027 to 2029, but paid a heavy price: the interest rate increased from 10% to 12%, triggering an $8.3M non-cash loss on debt extinguishment. The rising cost of capital is a severe headwind.
Guidance
Accelerating. Reaffirmed guidance implies a massive 106% YoY growth jump from FY25's $18.9M. However, with only $14.0M delivered in H1, the company must generate roughly $25.0M in H2. This steep sequential acceleration introduces extreme execution risk, heavily relying on international distributor readiness and unhindered supply chains.
Key Questions
Margin Bridge for Direct Sales
With gross margins settling at 41% under U.S. distributor models, what is the expected gross margin profile as the newly expanded direct sales force begins securing enterprise contracts?
H2 Execution Risk
To hit the $39M guidance, H2 revenue needs to be nearly double H1. How much of this back-half target is secured by non-cancelable POs versus anticipated new orders?
Path to Cash Flow Breakeven
Operating cash burn accelerated to $4.8M this quarter. At what revenue scale or scanner install base does the company expect to achieve operating cash flow breakeven, particularly as OpEx scales?
SaaS Monetization Timeline
You highlight the evolution toward a SaaS and AI-enabled clinical platform. When will recurring software revenue be broken out as a standalone reporting metric, and what is the current attach rate of the QTI Precision Pathway for new scanner sales?